MAY 14, 2020 7:52 PM PDT

Therapeutic for Gastrointestinal Tumors

WRITTEN BY: Nouran Amin

The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST). The therapeutic is approved for use in adults who have previously received treatment with 3 or more kinase inhibitor therapies, including imatinib, sunitinib, and regorafenib. When patients do not respond to these treatments, they may be prescribed Qinlock.

GIST results when abnormal cells form in the tissues of the gastrointestinal tract. These tumors most likely form in the stomach, small intestine, and large intestine.

Learn more about GIST, which affects roughly 6,000 adults annually in the United States:

“GIST is a complex disease and the majority of patients who initially respond to traditional tyrosine kinase inhibitors eventually develop tumor progression due to secondary mutations,” said Margaret von Mehren, MD, chief of sarcoma oncology and associate director for clinical research at Fox Chase Cancer Center.

Treatment for GIST using Qinlock was granted approval after findings of the INVICTUS study through the Fast Track designation and Priority Review by the FDA, in addition to the Breakthrough Therapy designation.

Some noted side-effects of Qinlcok use includes alopecia, fatigue, vomiting, and a variety of additional gastrointestinal complications. Treatment may also adversely affect a developing fetus during pregnancy and may be a risk for skin cancer, hypertension, and cardiac dysfunction.

“In the INVICTUS study, Qinlock has demonstrated compelling clinical benefit in progression-free and overall survival. Qinlock is well tolerated and is a crucial new therapy for these patients with a high unmet need.”

Source: AJMC

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 14, 2020
Immunology
MAY 14, 2020
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
Antibodies are a powerful countermeasure against COVID-19. Not only can they relieve symptoms in patients experiencing s ...
JUN 10, 2020
Cannabis Sciences
JUN 10, 2020
Cannabis Temporarily Relieves PTSD Symptoms
PTSD (Post Traumatic Stress Disorder) is a mental disorder characterized by flashbacks, nightmares, and severe anxiety f ...
JUN 13, 2020
Cannabis Sciences
JUN 13, 2020
CBD Kills Brain Cancer Cells in Petri Dish
Cannabis products are not only popular for their psychoactive effects. An increasing number of companies and researchers ...
JUN 15, 2020
Drug Discovery & Development
JUN 15, 2020
FDA Approves HPV Vaccine to Prevent Throat Cancer
For around a decade, research has suggested that Gardasil, an HPV vaccine, could prevent throat cancer, a condition that ...
JUN 18, 2020
Drug Discovery & Development
JUN 18, 2020
FDA Cancels Emergency Approval for Hydroxychloroquine
The US Food and Drug Administration (FDA) has decided to cancel emergency use authorization for Hydroxychloroquine and C ...
JUN 12, 2020
Technology
JUN 12, 2020
How A Computer Sea Slug Can Get Addicted To A Drug
Sea slugs have long been used to study brain models especially in research concerned with memory and learning. Now, rese ...
Loading Comments...